135 related articles for article (PubMed ID: 9541081)
1. Faecal occult blood screening for colorectal cancer: is it cost-effective?
Whynes DK; Neilson AR; Walker AR; Hardcastle JD
Health Econ; 1998 Feb; 7(1):21-9. PubMed ID: 9541081
[TBL] [Abstract][Full Text] [Related]
2. Colorectal cancer screening: efficiency and effectiveness.
Gyrd-Hansen D; Søgaard J; Kronborg O
Health Econ; 1998 Feb; 7(1):9-20. PubMed ID: 9541080
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
Murphy J; Halloran S; Gray A
BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of colonoscopy in screening for colorectal cancer.
Sonnenberg A; Delcò F; Inadomi JM
Ann Intern Med; 2000 Oct; 133(8):573-84. PubMed ID: 11033584
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of fecal occult blood screening for colorectal cancer.
Lejeune C; Arveux P; Dancourt V; Béjean S; Bonithon-Kopp C; Faivre J
Int J Technol Assess Health Care; 2004; 20(4):434-9. PubMed ID: 15609792
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of screening for colorectal cancer: evidence from the Nottingham faecal occult blood trial.
Whynes DK;
J Med Screen; 2004; 11(1):11-5. PubMed ID: 15006108
[TBL] [Abstract][Full Text] [Related]
8. Option appraisal of population-based colorectal cancer screening programmes in England.
Tappenden P; Chilcott J; Eggington S; Patnick J; Sakai H; Karnon J
Gut; 2007 May; 56(5):677-84. PubMed ID: 17142648
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of screening by faecal occult blood testing for colorectal cancer in Australia.
Salkeld G; Young G; Irwig L; Haas M; Glasziou P
Aust N Z J Public Health; 1996 Apr; 20(2):138-43. PubMed ID: 8799087
[TBL] [Abstract][Full Text] [Related]
10. Limitations of the faecal occult blood test in screening for colorectal cancer.
Delcò F; Sonnenberg A
Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of faecal occult blood screening for colorectal cancer: results of the Nottingham trial.
Whynes DK
Crit Rev Oncol Hematol; 1999 Nov; 32(2):155-65. PubMed ID: 10612015
[No Abstract] [Full Text] [Related]
12. Filtering strategies in mass population screening for colorectal cancer: an economic evaluation.
Walker A; Whynes DK
Med Decis Making; 1992; 12(1):2-7. PubMed ID: 1538628
[TBL] [Abstract][Full Text] [Related]
13. Estimates of costs and effects of screening for colorectal cancer in the United States.
Byers T; Gorsky R
Cancer; 1992 Sep; 70(5 Suppl):1288-95. PubMed ID: 1387342
[TBL] [Abstract][Full Text] [Related]
14. Rehydration of guaiac-based faecal occult blood tests in mass screening for colorectal cancer. An economic perspective.
Walker AR; Whynes DK; Hardcastle JD
Scand J Gastroenterol; 1991 Feb; 26(2):215-8. PubMed ID: 2011707
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of colorectal cancer screening in the elderly.
Wagner JL; Herdman RC; Wadhwa S
Ann Intern Med; 1991 Nov; 115(10):807-17. PubMed ID: 1929029
[TBL] [Abstract][Full Text] [Related]
16. Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data.
Sekiguchi M; Igarashi A; Matsuda T; Matsumoto M; Sakamoto T; Nakajima T; Kakugawa Y; Yamamoto S; Saito H; Saito Y
Jpn J Clin Oncol; 2016 Feb; 46(2):116-25. PubMed ID: 26685321
[TBL] [Abstract][Full Text] [Related]
17. Markov's modeling for screening strategies for colorectal cancer.
Barouni M; Larizadeh MH; Sabermahani A; Ghaderi H
Asian Pac J Cancer Prev; 2012; 13(10):5125-9. PubMed ID: 23244122
[TBL] [Abstract][Full Text] [Related]
18. Options for screening for colorectal cancer in the Royal Air Force: a cost-effectiveness evaluation.
Daniels K; McKee M
J R Army Med Corps; 1995 Oct; 141(3):142-50. PubMed ID: 8568748
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing.
Wong CK; Lam CL; Wan YF; Fong DY
BMC Cancer; 2015 Oct; 15():705. PubMed ID: 26471036
[TBL] [Abstract][Full Text] [Related]
20. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
Hristova L; Hakama M
Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
